[8-K] 4D Molecular Therapeutics, Inc. Reports Material Event
4D Molecular Therapeutics announced that it furnished a press release reporting its financial results for the three months ended June 30, 2025. The Form 8-K references a press release titled "4DMT Reports Second Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones" as Exhibit 99.1 and includes an interactive data file as Exhibit 104. The company鈥檚 common stock trades on the Nasdaq Global Select Market under the ticker FDMT. The filing itself does not include numerical financial details in the text provided here; investors must consult Exhibit 99.1 for the full results and operational highlights.
4D Molecular Therapeutics ha comunicato di aver pubblicato un comunicato stampa relativo ai risultati finanziari per i tre mesi terminati il 30 giugno 2025. Il modulo Form 8-K fa riferimento a un comunicato intitolato "4DMT Reports Second Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones" come Allegato 99.1 e include un file di dati interattivi come Allegato 104. Le azioni ordinarie della societ脿 sono quotate sul Nasdaq Global Select Market con il simbolo FDMT. La nota qui riportata non contiene dettagli numerici; gli investitori devono consultare l'Allegato 99.1 per i risultati completi e i principali aggiornamenti operativi.
4D Molecular Therapeutics anunci贸 que difundi贸 un comunicado de prensa con sus resultados financieros para los tres meses terminados el 30 de junio de 2025. El Formulario 8-K hace referencia a un comunicado titulado "4DMT Reports Second Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones" como Anexo 99.1 e incluye un archivo de datos interactivos como Anexo 104. Las acciones ordinarias de la compa帽铆a cotizan en el Nasdaq Global Select Market bajo el s铆mbolo FDMT. La presentaci贸n aqu铆 no incluye cifras; los inversores deben consultar el Anexo 99.1 para ver los resultados completos y los aspectos operativos destacados.
4D Molecular Therapeutics電� 2025雲� 6鞗� 30鞚�搿� 膦呺霅� 攵勱赴鞐� 雽�頃� 鞛 鞁れ爜鞚� 氤措弰頃� 氤措弰鞛愲毳� 瓿店皽頄堧嫟瓿� 氚滍憸頄堨姷雼堧嫟. Form 8-K電� "4DMT Reports Second Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones"霛茧姅 鞝滊鞚� 氤措弰鞛愲毳� Exhibit 99.1搿� 彀胳“頃橁碃, 靸來樃鞛戩毄順� 雿办澊韯� 韺岇澕鞚� Exhibit 104搿� 韽暔頃橁碃 鞛堨姷雼堧嫟. 須岇偓鞚� 氤错喌欤茧姅 Nasdaq Global Select Market鞐� FDMT 韹办护搿� 靸侅灔霅橃柎 鞛堨姷雼堧嫟. 鞐赴 鞝滉车霅� 鞝滌稖 氍胳劀 氤鸽鞐愲姅 靾橃箻鞝� 鞛 靸侅劯臧� 韽暔霅橃柎 鞛堨 鞎婌溂氙�搿�, 韴瀽鞛愲摛鞚� 鞝勳泊 鞁れ爜瓿� 鞖挫榿 頃橃澊霛检澊韸鸽ゼ 頇曥澑頃橂牑氅� Exhibit 99.1鞚� 彀胳“頃挫暭 頃╇媹雼�.
4D Molecular Therapeutics a annonc茅 avoir publi茅 un communiqu茅 pr茅sentant ses r茅sultats financiers pour les trois mois clos le 30 juin 2025. Le formulaire 8-K renvoie 脿 un communiqu茅 intitul茅 "4DMT Reports Second Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones" en tant que Pi猫ce 99.1 et inclut un fichier de donn茅es interactif en tant que Pi猫ce 104. Les actions ordinaires de la soci茅t茅 sont cot茅es sur le Nasdaq Global Select Market sous le symbole FDMT. Le d茅p么t fourni ici ne comporte pas de d茅tails financiers chiffr茅s聽; les investisseurs doivent consulter la Pi猫ce 99.1 pour les r茅sultats complets et les principaux 茅l茅ments op茅rationnels.
4D Molecular Therapeutics gab bekannt, dass es eine Pressemitteilung mit den Finanzergebnissen f眉r die drei Monate zum 30. Juni 2025 ver枚ffentlicht hat. Das Formular 8-K verweist auf eine Pressemitteilung mit dem Titel "4DMT Reports Second Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones" als Anlage 99.1 und enth盲lt eine interaktive Datendatei als Anlage 104. Die Stammaktien des Unternehmens werden am Nasdaq Global Select Market unter dem K眉rzel FDMT gehandelt. Die hier wiedergegebene Einreichung enth盲lt keine numerischen Finanzangaben; Anleger m眉ssen Anlage 99.1 f眉r die vollst盲ndigen Ergebnisse und operativen Highlights hinzuziehen.
- Press release furnished as Exhibit 99.1, indicating the company publicly disclosed its second quarter 2025 results and operational milestones.
- Interactive data file (Exhibit 104) provided, facilitating access to structured data for analysts and investors.
- No financial figures are included in the filing text provided; the Form 8-K references results for the three months ended June 30, 2025 but does not present revenue, EPS, cash, or other metrics within this text.
Insights
TL;DR: Routine disclosure; press release furnished announcing Q2 results for period ended June 30, 2025, but no financial figures appear in the filing text.
The Form 8-K notifies the market that 4DMT publicly released its second quarter 2025 results and related milestones via a press release furnished as an exhibit. Furnishing the press release satisfies public disclosure obligations and signals that detailed operating and financial metrics should be available in Exhibit 99.1. Because the filing text provided here contains no revenue, expense, profitability, cash balance, or guidance figures, this 8-K itself is informational rather than a source of quantitative assessment.
TL;DR: The company complied with disclosure procedures by furnishing the press release and interactive data file; this is a routine, non-material update in isolation.
Furnishing the press release as Exhibit 99.1 and providing an Inline XBRL cover (Exhibit 104) are consistent with transparency and regulatory compliance for public companies. The filing informs stakeholders where to find the detailed results and operational milestones. In the absence of the exhibit鈥檚 contents, the 8-K does not on its own change the material picture for investors.
4D Molecular Therapeutics ha comunicato di aver pubblicato un comunicato stampa relativo ai risultati finanziari per i tre mesi terminati il 30 giugno 2025. Il modulo Form 8-K fa riferimento a un comunicato intitolato "4DMT Reports Second Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones" come Allegato 99.1 e include un file di dati interattivi come Allegato 104. Le azioni ordinarie della societ脿 sono quotate sul Nasdaq Global Select Market con il simbolo FDMT. La nota qui riportata non contiene dettagli numerici; gli investitori devono consultare l'Allegato 99.1 per i risultati completi e i principali aggiornamenti operativi.
4D Molecular Therapeutics anunci贸 que difundi贸 un comunicado de prensa con sus resultados financieros para los tres meses terminados el 30 de junio de 2025. El Formulario 8-K hace referencia a un comunicado titulado "4DMT Reports Second Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones" como Anexo 99.1 e incluye un archivo de datos interactivos como Anexo 104. Las acciones ordinarias de la compa帽铆a cotizan en el Nasdaq Global Select Market bajo el s铆mbolo FDMT. La presentaci贸n aqu铆 no incluye cifras; los inversores deben consultar el Anexo 99.1 para ver los resultados completos y los aspectos operativos destacados.
4D Molecular Therapeutics電� 2025雲� 6鞗� 30鞚�搿� 膦呺霅� 攵勱赴鞐� 雽�頃� 鞛 鞁れ爜鞚� 氤措弰頃� 氤措弰鞛愲毳� 瓿店皽頄堧嫟瓿� 氚滍憸頄堨姷雼堧嫟. Form 8-K電� "4DMT Reports Second Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones"霛茧姅 鞝滊鞚� 氤措弰鞛愲毳� Exhibit 99.1搿� 彀胳“頃橁碃, 靸來樃鞛戩毄順� 雿办澊韯� 韺岇澕鞚� Exhibit 104搿� 韽暔頃橁碃 鞛堨姷雼堧嫟. 須岇偓鞚� 氤错喌欤茧姅 Nasdaq Global Select Market鞐� FDMT 韹办护搿� 靸侅灔霅橃柎 鞛堨姷雼堧嫟. 鞐赴 鞝滉车霅� 鞝滌稖 氍胳劀 氤鸽鞐愲姅 靾橃箻鞝� 鞛 靸侅劯臧� 韽暔霅橃柎 鞛堨 鞎婌溂氙�搿�, 韴瀽鞛愲摛鞚� 鞝勳泊 鞁れ爜瓿� 鞖挫榿 頃橃澊霛检澊韸鸽ゼ 頇曥澑頃橂牑氅� Exhibit 99.1鞚� 彀胳“頃挫暭 頃╇媹雼�.
4D Molecular Therapeutics a annonc茅 avoir publi茅 un communiqu茅 pr茅sentant ses r茅sultats financiers pour les trois mois clos le 30 juin 2025. Le formulaire 8-K renvoie 脿 un communiqu茅 intitul茅 "4DMT Reports Second Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones" en tant que Pi猫ce 99.1 et inclut un fichier de donn茅es interactif en tant que Pi猫ce 104. Les actions ordinaires de la soci茅t茅 sont cot茅es sur le Nasdaq Global Select Market sous le symbole FDMT. Le d茅p么t fourni ici ne comporte pas de d茅tails financiers chiffr茅s聽; les investisseurs doivent consulter la Pi猫ce 99.1 pour les r茅sultats complets et les principaux 茅l茅ments op茅rationnels.
4D Molecular Therapeutics gab bekannt, dass es eine Pressemitteilung mit den Finanzergebnissen f眉r die drei Monate zum 30. Juni 2025 ver枚ffentlicht hat. Das Formular 8-K verweist auf eine Pressemitteilung mit dem Titel "4DMT Reports Second Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones" als Anlage 99.1 und enth盲lt eine interaktive Datendatei als Anlage 104. Die Stammaktien des Unternehmens werden am Nasdaq Global Select Market unter dem K眉rzel FDMT gehandelt. Die hier wiedergegebene Einreichung enth盲lt keine numerischen Finanzangaben; Anleger m眉ssen Anlage 99.1 f眉r die vollst盲ndigen Ergebnisse und operativen Highlights hinzuziehen.
FAQ
What did 4D Molecular Therapeutics (FDMT) disclose in this 8-K?
Does this 8-K include the numerical financial results for Q2 2025?
Where is FDMT listed and what is the ticker symbol?
Which exhibits were furnished with the Form 8-K?
Who signed the Form 8-K on behalf of 4DMT?
